MX2020007880A - Anticuerpos de mica/b y metodos de uso. - Google Patents
Anticuerpos de mica/b y metodos de uso.Info
- Publication number
- MX2020007880A MX2020007880A MX2020007880A MX2020007880A MX2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A MX 2020007880 A MX2020007880 A MX 2020007880A
- Authority
- MX
- Mexico
- Prior art keywords
- mica
- antibodies
- methods
- chain domains
- well
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862621892P | 2018-01-25 | 2018-01-25 | |
| PCT/US2019/015025 WO2019147863A2 (en) | 2018-01-25 | 2019-01-24 | Mica/b antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007880A true MX2020007880A (es) | 2021-05-14 |
Family
ID=67396240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007880A MX2020007880A (es) | 2018-01-25 | 2019-01-24 | Anticuerpos de mica/b y metodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210047417A1 (https=) |
| EP (1) | EP3743109A4 (https=) |
| JP (2) | JP7458993B2 (https=) |
| KR (1) | KR102731953B1 (https=) |
| CN (1) | CN112566659A (https=) |
| AU (1) | AU2019211411B2 (https=) |
| BR (1) | BR112020015142A2 (https=) |
| IL (1) | IL276187B1 (https=) |
| MX (1) | MX2020007880A (https=) |
| WO (1) | WO2019147863A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| MX2021001254A (es) | 2018-07-31 | 2021-05-12 | Cullinan Mica Corp | Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso. |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| CA3186062A1 (en) * | 2020-08-10 | 2022-02-17 | Marion BENEZECH | Cell surface mica and micb detection using antibodies |
| CN114369161B (zh) * | 2021-12-28 | 2023-06-23 | 合肥天港免疫药物有限公司 | Mica抗体及其应用 |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| JP2025512137A (ja) * | 2022-04-08 | 2025-04-16 | ディーツーエム バイオセラピューティクス リミテッド | 抗ｍｉｃａ／ｂ抗体及びその使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1857116A1 (en) * | 2006-05-19 | 2007-11-21 | Novoplant GmbH | Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus |
| BRPI0808551B1 (pt) * | 2007-03-01 | 2022-04-05 | Symphogen A/S | Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende |
| US8753640B2 (en) * | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
| HUE034044T2 (en) * | 2011-09-30 | 2018-01-29 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| EP2970490A4 (en) * | 2013-03-15 | 2017-04-26 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
| WO2015003114A1 (en) * | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
| KR102206029B1 (ko) * | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102763121B1 (ko) * | 2015-02-06 | 2025-02-04 | 내셔널 유니버시티 오브 싱가포르 | 치료적 면역 세포의 효능의 향상 방법 |
| US11780924B2 (en) * | 2016-06-21 | 2023-10-10 | University Of Oslo | HLA binding vaccine moieties and uses thereof |
-
2019
- 2019-01-24 CN CN201980018723.5A patent/CN112566659A/zh active Pending
- 2019-01-24 KR KR1020207023978A patent/KR102731953B1/ko active Active
- 2019-01-24 EP EP19743264.4A patent/EP3743109A4/en active Pending
- 2019-01-24 BR BR112020015142-4A patent/BR112020015142A2/pt unknown
- 2019-01-24 WO PCT/US2019/015025 patent/WO2019147863A2/en not_active Ceased
- 2019-01-24 IL IL276187A patent/IL276187B1/en unknown
- 2019-01-24 JP JP2020561600A patent/JP7458993B2/ja active Active
- 2019-01-24 AU AU2019211411A patent/AU2019211411B2/en active Active
- 2019-01-24 MX MX2020007880A patent/MX2020007880A/es unknown
-
2020
- 2020-07-24 US US16/938,554 patent/US20210047417A1/en not_active Abandoned
-
2023
- 2023-06-01 US US18/327,566 patent/US20240067731A1/en active Pending
- 2023-12-27 JP JP2023221150A patent/JP2024038169A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024038169A (ja) | 2024-03-19 |
| KR102731953B1 (ko) | 2024-11-20 |
| JP7458993B2 (ja) | 2024-04-01 |
| US20210047417A1 (en) | 2021-02-18 |
| RU2020128010A (ru) | 2022-02-25 |
| AU2019211411B2 (en) | 2025-11-27 |
| JP2021511387A (ja) | 2021-05-06 |
| WO2019147863A3 (en) | 2019-10-24 |
| EP3743109A4 (en) | 2021-11-10 |
| CA3089478A1 (en) | 2019-08-01 |
| BR112020015142A2 (pt) | 2021-01-05 |
| US20240067731A1 (en) | 2024-02-29 |
| KR20200115545A (ko) | 2020-10-07 |
| CN112566659A (zh) | 2021-03-26 |
| IL276187A (en) | 2020-09-30 |
| AU2019211411A1 (en) | 2020-08-20 |
| EP3743109A2 (en) | 2020-12-02 |
| WO2019147863A2 (en) | 2019-08-01 |
| IL276187B1 (en) | 2026-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007880A (es) | Anticuerpos de mica/b y metodos de uso. | |
| MX2022006578A (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos. | |
| CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
| MX2016003593A (es) | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. | |
| CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
| UY37779A (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
| CR20160425A (es) | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas | |
| MX2017015042A (es) | Anticuerpos cd123 y conjugados de los mismos. | |
| CL2017000888A1 (es) | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
| SA517381604B1 (ar) | أجسام مضادة ديمرية غير متجانسة جديدة | |
| MX380937B (es) | Anticuerpos dobles especificos. | |
| MX388018B (es) | Anticuerpos anti-pd1 y métodos de uso. | |
| CU20160118A7 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
| BR112017002422A2 (pt) | domínio de ligação a cd3 | |
| ECSP22097203A (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso | |
| CL2019001352A1 (es) | Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo. | |
| EA201691321A1 (ru) | Антитела и способы их применения | |
| ZA202101258B (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
| MX394735B (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| ECSP22097197A (es) | Anticuerpos que se dirigen a un complejo que comprende hlai no clásico y neoantígeno y sus métodos de uso | |
| BR112018003494A2 (pt) | anticorpo anti-epha4 | |
| MX2016014355A (es) | Metodo para seleccionar anticuerpos con interaccion del receptor de fc neonatal (fcrn) modificado. | |
| MX2019011585A (es) | Anticuerpos miltiespecificos estables. |